Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Synkrino Biotherapeutics
AddedMar 22, 2024
UpdatedJul 7, 2026
Synkrino Biotherapeutics

Synkrino Biotherapeutics

Seed

Discovering novel drug targets from patients' immune systems using AI + Immunology Discovery Engine. Providing monitoring for pediatric rheumatologists and developing rapid COVID-19 tests.

HQ
Berkeley, CA, US
Founded
2018
Accelerator
Y Combinator logoY CombinatorS18
Overview
Compare
Fundraising
Employees
Website

Synkrino Biotherapeutics is a biotech platform focused on discovering and developing novel drug targets from patients' immune systems using its AI + Immunology Discovery Engine. The company provides monitoring solutions for pediatric rheumatologists dealing with life-threatening conditions and is developing a rapid, portable field test for COVID-19.

Synkrino Biotherapeutics has made significant strides in leveraging AI for immunology, enhancing drug discovery, and public health screening. Its innovative approach has positioned it as a key player in both pediatric care and pandemic response.

Synkrino Biotherapeutics - Similar Companies

GEn1E Lifesciences logo

GEn1E Lifesciences

gen1e.com

Parallel Bio logo

Parallel Bio

parallel.bio

Serinus Biosciences logo

Serinus Biosciences

serinus.bio

Synthekine logo

Synthekine

synthekine.com

SynsoryBio logo

SynsoryBio

synsorybio.com

Synfini logo

Synfini

synfini.com

Pando Bioscience logo

Pando Bioscience

pando.bio

Immunocure Discovery Solutions logo

Immunocure Discovery Solutions

immunocure.us

Aibios logo

Aibios

aibios.com

CellChorus logo

CellChorus

cellchorus.com

Seismic Therapeutic logo

Seismic Therapeutic

ImmunoMind logo

ImmunoMind

Harmonic Discovery logo

Harmonic Discovery

Junction Bioscience logo

Junction Bioscience

junction.bio

Arpeggio Bio logo

Arpeggio Bio

arpeggiobio.com

Synkrino Biotherapeutics - Quick Facts

Who are Synkrino Biotherapeutics' competitors?

Companies similar to Synkrino Biotherapeutics include GEn1E Lifesciences, Parallel Bio, Serinus Biosciences and Synthekine.

When was Synkrino Biotherapeutics founded?

Synkrino Biotherapeutics was founded in 2018.

Where is Synkrino Biotherapeutics' headquarters located?

Synkrino Biotherapeutics' headquarters is located in Berkeley, CA, US.

When was Synkrino Biotherapeutics' last funding round?

Synkrino Biotherapeutics' most recent funding round was for $120k (USD) in August 2018.

How much has Synkrino Biotherapeutics raised to-date?

As of Aug 23, 2018, Synkrino Biotherapeutics has raised a total of $120k (USD).

How many employees does Synkrino Biotherapeutics have?

Synkrino Biotherapeutics has 6 employees as of Feb 24, 2024.

Synkrino Biotherapeutics - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Biotech
  • Machine Learning
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Drug Discovery
  • Therapeutics
Tags
  • Platform
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software